Disease/Infection News

RSS

UCLA researchers devise plan to reduce HIV transmission in Africa

While Ebola has attracted much of the world's attention recently, a severe HIV epidemic rages on around the world and in sub-Saharan Africa in particular. Globally, more than 34 million people are infected with HIV; in sub-Saharan Africa alone, 3 million new infections occur annually.

3 Dec 2014

Ceres to develop new method for detecting the presence of Ebola virus in saliva

Ceres Nanosciences Inc. today announced the commencement of a development program, funded by the Gates Foundation, to use Ceres' Nanotrap particle technology to develop a new method of detecting the presence of the Ebola virus in saliva.

3 Dec 2014

Researchers create synthetic surface to control adhesion of E. coli bacteria

A research team from Kiel University and Goethe University Frankfurt has jointly created a synthetic surface on which the adhesion of E. coli bacteria can be controlled. The layer, which is only approximately four nanometres thick, imitates the saccharide coating (glycocalyx) of cells onto which the bacteria adhere such as during an infection. This docking process can be switched on and off using light.

3 Dec 2014

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University and 60P Australia Pty Ltd, a subsidiary of 60° Pharmaceuticals LLC, have announced today an exclusive partnering deal, with 60P obtaining rights to develop the drug Fenretinide for dengue fever.

2 Dec 2014

EU-designed forecasting model developed to predict spread of Ebola

Forecasters predicting the spread of Ebola are using one of the most sophisticated modeling systems in the world - the result of an EU research project.

2 Dec 2014

InnaVirVax receives DSMB recommendation to pursue VAC-3S Phase 2 study in HIV

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, today announces the recommendation of its independent Data Safety and Monitoring Board (DSMB) to pursue the Phase 2 study (IPROTECT1) of VAC-3S according to the planned protocol.

2 Dec 2014

HIV's ability to cause AIDS is declining, finds new research

The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS, according to new research funded by the Wellcome Trust.

2 Dec 2014

New cellPACK software can help explore human cells in more detail

Researchers can now explore viruses, bacteria and components of the human body in more detail than ever before with software developed at The Scripps Research Institute.

2 Dec 2014

(RED) raises money for ‘Global Fund to fight AIDS, Tuberculosis and Malaria’

As the world reaches a tipping point in the AIDS fight, (RED) and its iconic partners Apple, Bank of America, The Coca-Cola Company and Starbucks marked World AIDS Day 2014 by rallying millions of people around the AIDS fight, and raising money for the Global Fund to fight AIDS, TB and Malaria.

2 Dec 2014

Restrooms are no more healthy, unhealthy than your home

Microbial succession in a sterilized restroom begins with bacteria from the gut and the vagina, and is followed shortly by microbes from the skin. Restrooms are dominated by a stable community structure of skin and outdoor associated bacteria, with few pathogenic bacteria making them similar to other built environments such as your home.

2 Dec 2014

Researchers develop low-cost, electricity-free device for detecting DNA of infectious pathogens

Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers funded by the National Institutes of Health have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.

2 Dec 2014

Antibiotic resistance: Theme for next Uppsala Health Summit

The theme for the next Uppsala Health Summit, to be held in Uppsala on 2-3 June 2015, is antibiotic resistance -- one of the biggest global health challenges of our day.

2 Dec 2014

Researchers identify infection control gaps as major culprit in spread of MERS-CoV

Little is known about the often fatal virus known as Middle East respiratory syndrome coronavirus (MERS-CoV), but researchers have identified gaps in infection control as a major culprit in all eleven published cases involving healthcare-associated transmission of the virus.

2 Dec 2014

Mylan, CAS to raise funds and awareness for people living with HIV/AIDS

Mylan Inc. and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for Canadians and people worldwide who are living with or at risk of HIV/AIDS.

2 Dec 2014

SIM physicians available to speak on Ebola epidemic ahead of International Volunteer Day

Two SIM USA physicians — one a long-term veteran and the second a new, short-term volunteer — are headed to Ebola-stricken West Africa and available to speak this week in advance of International Volunteer Day, Dec. 5, on a variety of topics related to the outbreak, the healthcare crisis in the region, and the role and need for volunteers.

1 Dec 2014

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs.

1 Dec 2014

Cepheid gets FDA clearance to market Xpert Norovirus

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market Xpert Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII).

1 Dec 2014